On July 13, 2026, the FDA approved Leqembi Iqlik (lecanemab-irmb) as a weekly at-home starting dose for early Alzheimer's disease. This checklist helps people with mild cognitive impairment, or MCI, prepare for that start with a clinician and caregiver. Leqembi Iqlik is a subcutaneous anti-amyloid treatment, meaning it targets amyloid-beta protein and is given by shot under the skin. According to the FDA approval notice, the FDA described it as the first anti-amyloid Alzheimer's treatment patients can start at home by themselves or with a caregiver.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Apply through FDA’s official page — Use this page to review requirements and apply directly.
- Read the official guidance from Caremark — Use this primary source to verify the official guidance.
Table of Contents
- Who is this starting dose for?
- What does the weekly at-home dose look like?
- What should you line up before the first dose?
- What safety follow-up still needs a clinic?
Who is this starting dose for?
This option is for adults with early Alzheimer's disease. That means MCI or mild dementia with confirmed amyloid-beta pathology, the same type of patient studied in trials. Amyloid confirmation comes first. A memory clinic usually checks it with PET scan or spinal fluid testing.
Without that proof, treatment does not fit. A dementia specialist should confirm the stage and rule out other causes. Early symptoms can come from sleep apnea, depression, thyroid problems, or medication effects. That visit also sets a baseline for thinking, daily function, and other drugs.
What does the weekly at-home dose look like?
Eisai reports the starting regimen is 500 mg once weekly, given as two consecutive 250 mg autoinjector shots. According to the Eisai announcement, each injection takes about 15 seconds. No hospital or infusion-center visit is needed for the shot itself. A person can do it alone or with a caregiver after training.
Storage, handling, travel plans, and sharps disposal still need a clear home routine. BioArctic announced U.S. availability on August 24, 2026, after planned specialty-pharmacy distribution in late August. According to the BioArctic launch update, families can ask their clinic which specialty pharmacy will fill and ship the autoinjectors.
What should you line up before the first dose?
Use these checks to prepare for the prescribing visit: Bring a full medication list, including blood thinners and antiplatelet drugs. Bring emergency contacts, allergy history, and prior brain bleeds or swelling. Ask who to call for headache, confusion, vision change, dizziness, or falls.
Practice the two-shot sequence during training. Check where to inject, how to hold the device, how to time the shots, and what to do after a missed or partial dose. Keep written steps near the medicine.
- Confirm amyloid-beta pathology and early-stage diagnosis
- Obtain a recent brain MRI and share prior scans
- Schedule dementia-specialist review of risks, benefits, and other medicines
- Arrange autoinjector training and a backup caregiver
- Set a plan for clinician contact and MRI follow-up
What safety follow-up still needs a clinic?
Home dosing does not remove clinic monitoring. Lecanemab carries a boxed warning for amyloid-related imaging abnormalities, or ARIA, involving brain swelling or bleeding. Labeling calls for a baseline brain MRI and periodic MRI checks during treatment. Keep every MRI appointment, even when memory feels stable.
ARIA can occur without clear symptoms at first. A scheduled scan is often how a care team finds it early. Report new headache, confusion, trouble speaking, weakness, vision change, dizziness, nausea, or unsteady walking right away. Do not pause or restart shots without clinician direction. Keep the specialist, primary care clinician, and MRI center linked so results reach the prescriber fast.
You Might Also Like
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- NIA’s 2026 Late-Life Depression and Dementia Workshop: What Researchers Still Need to Learn for Adults With Memory Concerns
- Subjective Cognitive Decline Data for Public Health Action in 2026: Data Questions Adults in Midlife Should Ask
